{"id":97955,"date":"2026-06-02T16:18:39","date_gmt":"2026-06-02T16:18:39","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/97955\/"},"modified":"2026-06-02T16:18:39","modified_gmt":"2026-06-02T16:18:39","slug":"is-novo-nordisk-a-s-nvo-expanding-its-lead-in-diabetes-and-weight-loss-ahead-of-ada-conference","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/97955\/","title":{"rendered":"Is Novo Nordisk A\/S (NVO) Expanding Its Lead in Diabetes and Weight Loss Ahead of ADA Conference?"},"content":{"rendered":"\n<p class=\"yf-1fy9kyt\">We recently compiled a list of the <a href=\"https:\/\/www.insidermonkey.com\/blog\/11-most-undervalued-pharma-stocks-to-invest-in-1770750\/?singlepage=1\" rel=\"nofollow noopener\" target=\"_blank\" data-ylk=\"slk:11 Most Undervalued Pharma Stocks to Invest In;elm:context_link;itc:0;sec:content-canvas\" data-yga=\"{&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yLinkText&quot;:&quot;11 Most Undervalued Pharma Stocks to Invest In&quot;}\" class=\"link \">11 Most Undervalued Pharma Stocks to Invest In<\/a>. Novo Nordisk A\/S (NYSE:NVO) is one of the most undervalued stocks\u00a0to invest in.<\/p>\n<p class=\"yf-1fy9kyt\">TheFly reported on May 27 that NVO announced that it will present new clinical findings from its cardiometabolic portfolio at the 2026 Scientific Sessions of the American Diabetes Association in New Orleans, scheduled for June 5\u20138, 2026. The company plans to showcase results from its Phase 3 REIMAGINE program evaluating investigational CagriSema on blood sugar control and weight reduction across multiple type 2 diabetes treatment backgrounds. In total, 40 scientific abstracts will be presented at the meeting. This includes Phase 2 data on the safety and efficacy of once-weekly injectable zenagamtide, along with updated clinical evidence for Ozempic and Wegovy, further expanding research on semaglutide across several cardiometabolic indications.<\/p>\n<p>    <img fetchpriority=\"high\" decoding=\"async\" src=\"https:\/\/www.europesays.com\/dk\/wp-content\/uploads\/2026\/06\/a064853e8ae32f3fc68f2ca03dab9b6d.jpeg\" alt=\"Is Novo Nordisk A\/S (NVO) Expanding Its Lead in Diabetes and Weight Loss Ahead of ADA Conference?\" loading=\"eager\" height=\"538\" width=\"960\" class=\"yf-lglytj  loaded\"\/> Is Novo Nordisk A\/S (NVO) Expanding Its Lead in Diabetes and Weight Loss Ahead of ADA Conference?      <\/p>\n<p class=\"yf-1fy9kyt\">Separately, earlier on May 12, Novo Nordisk A\/S (NYSE:NVO) presented new clinical and real-world evidence for Wegovy (semaglutide 2.4 mg and 7.2 mg) at the European Congress on Obesity 2026 in Istanbul. The data showed consistent and significant weight reduction in women with obesity across different stages of reproductive life, including premenopause, perimenopause, menopause, and postmenopause. Findings were drawn from the STEP UP trial, the SELECT cardiovascular outcomes study, and a large real-world analysis. Results also indicated improvements in waist circumference, body composition, cardiovascular risk reduction, and quality of life measures such as migraine, depression, and menopause-related symptoms, reinforcing semaglutide\u2019s broader cardiometabolic benefits.<\/p>\n<p class=\"yf-1fy9kyt\">Novo Nordisk A\/S (NYSE:NVO) is a global healthcare company focused on diabetes, obesity, and rare bleeding disorders. Headquartered in Denmark, it is one of the world\u2019s largest insulin producers.<\/p>\n<p class=\"yf-1fy9kyt\">While we acknowledge the potential of NVO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you&#8217;re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the<a href=\"https:\/\/www.insidermonkey.com\/blog\/three-megatrends-one-overlooked-stock-massive-upside-1548959\/\" rel=\"nofollow noopener\" target=\"_blank\" data-ylk=\"slk:best short-term AI stock;elm:context_link;itc:0;sec:content-canvas\" data-yga=\"{&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yLinkText&quot;:&quot;best short-term AI stock&quot;}\" class=\"link \"> best short-term AI stock<\/a>.<\/p>\n<p class=\"yf-1fy9kyt\">READ NEXT: <a href=\"https:\/\/www.insidermonkey.com\/blog\/12-best-strong-buy-tech-stocks-to-invest-in-now-1768379\/\" rel=\"nofollow noopener\" target=\"_blank\" data-ylk=\"slk:12 Best Strong Buy Tech Stocks to Invest In Now;elm:context_link;itc:0;sec:content-canvas\" data-yga=\"{&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yLinkText&quot;:&quot;12 Best Strong Buy Tech Stocks to Invest In Now&quot;}\" class=\"link \">12 Best Strong Buy Tech Stocks to Invest In Now<\/a> and <a href=\"https:\/\/www.insidermonkey.com\/blog\/10-most-widely-held-stocks-by-individuals-in-2026-1767654\/\" rel=\"nofollow noopener\" target=\"_blank\" data-ylk=\"slk:10 Most Widely Held Stocks by Individuals in 2026\u00a0;elm:context_link;itc:0;sec:content-canvas\" data-yga=\"{&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yLinkText&quot;:&quot;10 Most Widely Held Stocks by Individuals in 2026&amp;nbsp&quot;}\" class=\"link \">10 Most Widely Held Stocks by Individuals in 2026\u00a0<\/a>.<\/p>\n<p class=\"yf-1fy9kyt\">Disclosure: None. <a href=\"https:\/\/news.google.com\/publications\/CAAqLQgKIidDQklTRndnTWFoTUtFV2x1YzJsa1pYSnRiMjVyWlhrdVkyOXRLQUFQAQ?hl=en-US&amp;gl=US&amp;ceid=US%3Aen\" rel=\"nofollow noopener\" target=\"_blank\" data-ylk=\"slk:Follow Insider Monkey on Google News;elm:context_link;itc:0;sec:content-canvas\" data-yga=\"{&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yLinkText&quot;:&quot;Follow Insider Monkey on Google News&quot;}\" class=\"link \">Follow Insider Monkey on Google News<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"We recently compiled a list of the 11 Most Undervalued Pharma Stocks to Invest In. Novo Nordisk A\/S&hellip;\n","protected":false},"author":2,"featured_media":97956,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[2641,50629,272,3102,3523,12795],"class_list":["post-97955","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-american-diabetes-association","tag-clinical-evidence","tag-novo-nordisk","tag-ozempic","tag-undervalued-stocks","tag-weight-reduction"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116681422045044633","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/97955","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=97955"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/97955\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/97956"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=97955"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=97955"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=97955"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}